-
Brean Predicts 'A Skid And A Crash' For Rockwell Medical's Triferic Drug
Monday, January 26, 2015 - 5:25pm | 222Read More...Brean Capital reiterated its Sell rating on Rockwell Medical Inc (NASDAQ: RMTI) on Monday following the FDA approval of its Triferic iron replacement product. The firm maintained a $4 price target. Analysts Jonathan Aschoff and Yi Cheng expected “dismal commercial uptake” for the...
